Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 1,576Xls
2D Structure
Also known as: 611168-24-2, Ravicti, Hpn-100, Glycerolphenylbutyrate, Gt4p, Hpn100
Molecular Formula
C33H38O6
Molecular Weight
530.6  g/mol
InChI Key
ZSDBFLMJVAGKOU-UHFFFAOYSA-N
FDA UNII
ZH6F1VCV7B

Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate
2.1.2 InChI
InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2
2.1.3 InChI Key
ZSDBFLMJVAGKOU-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3
2.2 Other Identifiers
2.2.1 UNII
ZH6F1VCV7B
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hpn 100

2. Hpn-100

3. Hpn100

4. Ravicti

2.3.2 Depositor-Supplied Synonyms

1. 611168-24-2

2. Ravicti

3. Hpn-100

4. Glycerolphenylbutyrate

5. Gt4p

6. Hpn100

7. Propane-1,2,3-triyl Tris(4-phenylbutanoate)

8. Zh6f1vcv7b

9. Glycerol Phenylbutyrate [usan]

10. Glycerol Phenylbutyrate (usan)

11. Benzenebutanoic Acid, 1,1',1''-(1,2,3-propanetriyl) Ester

12. Unii-zh6f1vcv7b

13. Tris(4-phenylbutyryl)glycerol

14. Glyceryl Tri-4-phenylbutyrate

15. Glyceryl Tri-(4-phenylbutyrate)

16. Hpn 100

17. Glycerol Phenylbutyrate [usan:inn]

18. Ravicti (tn)

19. Glycerol-phenylbutyrate

20. 2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate

21. Chembl2105745

22. Schembl10102804

23. Dtxsid40210005

24. Hpn-100hpn-100

25. Chebi:134745

26. Hy-b2087

27. Glycerol Phenylbutyrate [mi]

28. Tri(4-phenylbutyryl)glycerol

29. Glycerol Phenylbutyrate [inn]

30. S6981

31. Glyceryl Tri(4-phenylbutyrate)

32. At33615

33. Db08909

34. Glycerol Phenylbutyrate [vandf]

35. Glycerol Phenylbutyrate [who-dd]

36. Glyceryl Tri (4-phenylbutyrate)

37. Cs-0017499

38. Glycerol Phenylbutyrate [orange Book]

39. D10127

40. Q15322709

41. Benzenebutanoic Acid, 1,2,3-propanetriyl Ester

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 530.6 g/mol
Molecular Formula C33H38O6
XLogP36.7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count20
Exact Mass530.26683893 g/mol
Monoisotopic Mass530.26683893 g/mol
Topological Polar Surface Area78.9 Ų
Heavy Atom Count39
Formal Charge0
Complexity648
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameRavicti
PubMed HealthGlycerol Phenylbutyrate (By mouth)
Drug ClassesHyperammonemia Agent
Drug LabelRAVICTI (glycerol phenylbutyrate) is a clear, colorless to pale yellow oral liquid. It is insoluble in water and most organic solvents, and it is soluble in dimethylsulfoxide (DMSO) and >65% acetonitrile.Glycerol phenylbutyrate is a nitrogen-binding...
Active IngredientGlycerol phenylbutyrate
Dosage FormLiquid
RouteOral
Strength1.1gm/ml
Market StatusPrescription
CompanyHyperion Therap

2 of 2  
Drug NameRavicti
PubMed HealthGlycerol Phenylbutyrate (By mouth)
Drug ClassesHyperammonemia Agent
Drug LabelRAVICTI (glycerol phenylbutyrate) is a clear, colorless to pale yellow oral liquid. It is insoluble in water and most organic solvents, and it is soluble in dimethylsulfoxide (DMSO) and >65% acetonitrile.Glycerol phenylbutyrate is a nitrogen-binding...
Active IngredientGlycerol phenylbutyrate
Dosage FormLiquid
RouteOral
Strength1.1gm/ml
Market StatusPrescription
CompanyHyperion Therap

4.2 Drug Indication

Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients 2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.


FDA Label


Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e. g. , essential amino acids, arginine, citrulline, protein-free calorie supplements).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Glycerol phenylbutyrate prolongs the QTc interval.


5.2 ATC Code

A16AX09


A - Alimentary tract and metabolism

A16 - Other alimentary tract and metabolism products

A16A - Other alimentary tract and metabolism products

A16AX - Various alimentary tract and metabolism products

A16AX09 - Glycerol phenylbutyrate


5.3 Absorption, Distribution and Excretion

Absorption

Glycerol phenylbutyrate is a prodrug in which phenylbutyrate (PBA) is released from the glycerol backbone by lipases in the gastrointestinal tract. PBA then undergoes beta-oxidtion to form PAA. When a single oral dose of 2.9 mL/m2 of Glycerol phenylbutyrate is given to fasting adult subjects, the pharmacokinetic parameters are as follows: Tmax: PBA = 2 hours; PAA = 4 hours; PAGN = 4 hours. Cmax: PBA = 37.0 g/mL; PAA = 14.9 g/mL; PAGN = 30.2 g/mL. In healthy subjects, the hydrolysis of glycerol phenylbutyrate is incomplete, but to what extent is unknown. When glycerol phenylbutyrate is given to adult UCD patients, maximum plasma concentrations at steady state (Cmaxss) of PBA, PAA, and PAGN occurred at 8 h, 12 h, and 10 h, respectively, after the first dose in the day. Intact glycerol phenylbutyrate was not detectable in plasma in UCD patients.


Route of Elimination

Glycerol phenylbutyrate is mainly excreted as PAGN in the urine (68.9% in adults and 66.5% in pediatric UCD patients). PAA and PBA represented minor urinary metabolites, each accounting for <1% of the administered dose of PBA.


5.4 Metabolism/Metabolites

Pancreatic lipases hydrolyze glycerol phenylbutyrate to release PBA from the glycerol backbone. PBA undergoes -oxidation to PAA, which is conjugated with glutamine in the liver and in the kidney through the enzyme phenylacetyl-CoA: L-glutamine-N-acetyltransferase to form PAGN.


5.5 Mechanism of Action

The toxic accumulation of ammonia in the blood and brain arise from urea cycle disorders in which patients are deficient in critical enzymes or transporters that are involved in the synthesis of urea from ammonia. Glycerol phenylbutyrate is a prodrug - the major metabolite, phenylacetate (PAA) is the molecule that binds to nitrogen. PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form phenylacetylglutamine (PAGN), which is excreted by the kidneys. PAGN, like urea, contains 2 moles of nitrogen and provides an alternate vehicle for waste nitrogen excretion.